Cylite Pty Ltd

At Cylite, we’re committed to redefining and improving the future of eye health. Since 2013, our passionate team of Australian researchers and innovators has been developing a novel OCT to assist optometry, ophthalmology and research specialists as they continue to strive for better patient outcomes.

The story so far

In 2012, OCT had advanced to a point that it had changed the way optometry and ophthalmology was practiced. Despite that, clinicians were still facing the problem of eye movement artefacts, which inhibited their ability to acquire scans featuring sufficiently accurate eye measurements, especially in the anterior segment.

Utilising their more than 80 years’ of combined experience in optics, the Cylite founding team set out to change that. Having grown a number of companies in the optical and telecommunications space, which have generated over $1bn in revenues, they had amassed a great understanding in the field and used this knowledge to sketch out a proposal – it was a completely different approach to OCT that was more relevant to measuring the surfaces and layers of the eye. These plans were soon formalised, patent applications were developed, and an optical engineer validated the technology.

Not only had they come up with an alternative technology for anterior segment imaging, they also found a way to image the retina.

Next step was to validate the concept with the relevant industry experts. This involved presenting their work at numerous science conferences, including Photonics West, BiOS (biomedical optics and biophotonics exhibition), Association for Research in Vision and Ophthalmology (ARVO) and Laser World of Photonics.

Many awarded patents later, the technology looks set to redefine a new generation of OCT in ophthalmology and optometry.